๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

โœ Scribed by Alan L. Whone; Ray L. Watts; A. Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E. Lang; Olivier Rascol; Maria J. Ribeiro; Philippe Remy; Werner H. Poewe; Robert A. Hauser; David J. Brooks

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
213 KB
Volume
54
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Onset of dyskinesia with adjunct ropinir
Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease
โœ Ray L. Watts; Kelly E. Lyons; Rajesh Pahwa; Kapil Sethi; Matthew Stern; Robert A ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 135 KB ๐Ÿ‘ 1 views

Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24hour prolonged-release (n 5 104) in PD patients not optimally controll

Sumanirole versus placebo or ropinirole
Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease
โœ Paolo Barone; Janice Lamb; Amanda Ellis; Zoe Clarke ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 171 KB

## Abstract The aims of this study were to assess the safety, tolerability, and efficacy of sumanirole, a highly selective D~2~ dopamine receptor agonist, versus placebo in subjects with advanced Parkinson's disease (PD), and to demonstrate noninferiority of sumanirole to ropinirole. In this flexib

Ropinirole in the treatment of early Par
Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study
โœ Dr. Olivier Rascol; David J. Brooks; Ehrout R. Brunt; Amos D. Korczyn; Warner H. ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 785 KB

The efficacies of ropinirole and levodopa were compared after 6 months of treatment in a planned interim analysis of a 5-year, double-blind, randomized, multicenter study of patients with early Parkinson's disease requiring dopaminergic therapy. The percentage of improvement in the Unified Parkinson

A comparison of sumanirole versus placeb
A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease
โœ Carlos Singer; Janice Lamb; Amanda Ellis; Gary Layton ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 146 KB ๐Ÿ‘ 1 views

## Abstract To assess the safety and efficacy of sumanirole, a highly selective dopamine agonist, versus placebo and demonstrate its noninferiority to ropinirole, 614 patients with early Parkinson's disease (PD) were treated with sumanirole, 1 to16 mg/day; ropinirole, 0.75 to 24 mg/day; or placebo.